WO1998048890A1 - Method and apparatus for electrical stimulation of the gastrointestinal tract - Google Patents

Method and apparatus for electrical stimulation of the gastrointestinal tract Download PDF

Info

Publication number
WO1998048890A1
WO1998048890A1 PCT/US1998/006831 US9806831W WO9848890A1 WO 1998048890 A1 WO1998048890 A1 WO 1998048890A1 US 9806831 W US9806831 W US 9806831W WO 9848890 A1 WO9848890 A1 WO 9848890A1
Authority
WO
WIPO (PCT)
Prior art keywords
frequency
sensing
gastrointestinal
sensor
activity
Prior art date
Application number
PCT/US1998/006831
Other languages
French (fr)
Inventor
Ivan Bourgeois
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to AU67967/98A priority Critical patent/AU6796798A/en
Publication of WO1998048890A1 publication Critical patent/WO1998048890A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control

Definitions

  • the invention relates to treatment of gastrointestinal disorders using a method and apparatus for providing electrical stimulation of the gastrointestinal tract.
  • the gastrointestinal tract is responsible for an essential step in the digestive process, the reception of nutrition in the human body.
  • An important element of the digestive process is peristalsis, the coordinated and self-regulated motor activity of the intestinal tract. Peristalsis is accomplished through a coordinated combination of electrical, chemical, neurological and hormonal mediation, as well as possibly other, as yet unknown, mechanisms.
  • Many diseases and maladies can affect the motor activity of the gastrointestinal tract, causing malfunction of the digestive process. Such diseases include diabetes mellitus, scleroderma, intestinal pseudo-obstruction, ileus, and gastroparesis.
  • Gastroparesis for example, is a chronic gastric motility disorder in which there is delayed gastric emptying of solids and/or liquids. Symptoms of gastroparesis may range from early satiety and nausea in mild cases to chronic vomiting, dehydration, and nutritional compromise in severe cases. Diagnosis of gastroparesis is based on demonstration of delayed gastric emptying of a radio- labeled solid meal in the absence of mechanical obstruction. Gastroparesis may occur for a number of reasons. Approximately one third of patients with gastroparesis, however, have no identifiable underlying cause (often called idiopathic gastroparesis).
  • Gastroparesis is often a chronic, relapsing condition; 80% of patients require maintenance antiemetic and prokinetic therapy and 20%> require long-term nutritional supplementation.
  • Other maladies such as tachygastria or bradygastria can also hinder coordinated muscular motor activity of the gastrointestinal tract, possibly resulting in either stasis or nausea or vomiting or a combination thereof.
  • the present invention is a method and apparatus for providing electrical stimulation of the gastrointestinal tract.
  • the apparatus features an implantable pulse generator which may be coupled to the gastric system through one or more medical electrical leads.
  • the leads couple to the circular layer of the stomach.
  • the pulse generator preferably features sensors for sensing gastric electrical activity, and in particular, whether peristaltic contractions as occurring.
  • two sensors are featured. The first sensor senses low frequency gastrointestinal electrical activity between the frequency of approximately 0.005 Hz - 5 Hz (“slow waves”) and the second sensor senses intrinsic gastrointestinal electrical activity between the frequency of approximately 100 - 5000 Hz ("spike activity”) which occurs upon normal peristaltic contractions and immediately follows a slow wave.
  • the second sensor only senses for a preset period after a slow waves has been sensed by the first sensor.
  • the pulse generator further delivers stimulation pulse trains to the gastrointestinal tract at a period of time after slow waves have been sensed by the first sensor. If, however, the second sensor senses a sufficient amount of spike activity, then the delivery of stimulation pulse trains to the gastrointestinal tract is inhibited. In such a manner the present invention detects the occurrence of normal peristaltic contractions and further provides electrical stimulation to the gastrointestinal tract if such normal peristaltic contractions are not detected.
  • FIG. 1 depicts the apparatus implanted within a patient.
  • FIG. 2 depicts a detailed view of the stomach muscle showing the electrode of the lead implanted.
  • FIG. 3 depicts a plan view of a lead used with the apparatus.
  • FIG. 4 is a functional block diagram of the pulse generator.
  • FIG. 5 is an electrogastrogram of the gastrointestinal system.
  • FIG. 6 is an electrogastrogram illustrating an arrhythmia and the response of the apparatus.
  • FIG. 7 is a flowchart depicting the operation of the system.
  • FIG. 8a-8e depict various pulse trains which may be emitted by the present system.
  • FIG. 9 depicts the steps used in the present invention to determine contraction or vomiting or other changes in the stomach using plethsmography.
  • FIG. 10 depicts the electrical stimulation delivered in the normal mode of the device.
  • FIGS are not necessarily to scale.
  • FIG. 1 shows a system 1 implanted in a patient 2.
  • the system 1 comprises an implantable pulse generator 3 featuring two sets of leads 4, 5 which are coupled to the stomach 10.
  • the first set of leads 4 provide stimulation to the stomach.
  • the second set of leads 5 provide sensing of the gastroelectrical activity of the stomach 10 to the pulse generator 3.
  • the pulse generator 3 In the preferred embodiment, the pulse generator
  • the implantable pulse generator 3 is implanted within the patient 2.
  • the implantable pulse generator 3 features a hermetic enclosure, as is well known in the art.
  • the leads used for both the first set 4 and the second set 5 may be any acceptable lead.
  • the preferred leads are Medtronic Model No. 4300 intramuscular lead.
  • other configurations of leads or lead systems may be used, including the use of from only a single lead, a single set of leads (i.e. two), or even the use of three or more sets of leads.
  • the present invention may be used along or on any of the other structures and organs along the gastrointestinal tract, including the colon, small intestine, stomach or even the esophagus.
  • the first set of leads 4 are stimulation leads which conduct stimulation pulses from the pulse generator 3 to the stomach 10.
  • First set of leads 4 are preferably implanted through the serosa at the area within the transition of the corpus and the antrum on the great curvature.
  • Other locations for first set of leads 4 may be used, such as in the fundus, caudud corpus as well as the orad or terminal antrum.
  • the second set of leads 5 are sensing leads which conduct any gastroelectrical activities sensed in the stomach 10 to the pulse generator 3.
  • the second set of leads 5 are positioned distally in the mid antrum also along the great curvature, although these leads may also be positioned in other locations.
  • FIG. 2 details the preferred positioning of an electrode of a lead within the various layers of the stomach.
  • the stomach 10 has essentially seven layers of tissue.
  • the electrode of each lead is positioned into the layers of the stomach muscle as shown. That is, the electrode is positioned such that it intersects both the longitudinal and circular layers. This is believed important by the inventor because in such a manner the electrode is able to also intersect the enteric nervous system of the stomach and be in close contact with the cells of Cajal.
  • FIG. 3 depicts a plan view of the preferred embodiment lead 15 used in the present invention.
  • the lead 15 essentially has three sections, connector section 16, body section 17 and fixation section 18.
  • Connector section 16 includes a connector pin 22 to electrically couple the lead 15 into the pulse generator. Any connector pin 22 as well known in the art may be used.
  • Body section 17 includes an electrical conductor 19 surrounded by an electrical insulator 20.
  • electrical conductor 19 is a platinum iridium alloy and electrical insulator 18 is silicone. Of course, other biocompatible materials may also be used.
  • electrode 25 is a polished platinum iridium alloy. Of course, other materials may likewise be used, such as a porous platinized structure.
  • the electrode 25 could further feature various pharmaceutical agents, such as dexamethasone sodium phosphate or beclomethasone phosphate in order to minimize the inflammatory response of the tissue to the implanted lead 15. Other agents such as antibiotics may also be used.
  • fixation section 18 Located distal to the electrode 25 is the fixation section 18.
  • fixation section 18 has essentially two piece parts, a suture 26 which is in turn coupled to a needle 27. Needle 27 is preferably curved.
  • suture may feature a fixation coil as is well known in the art to cooperate with the body tissue after implantation to maintain the lead 15 in the position implanted.
  • fixation mechanisms may be used, such as fixation discs, as is well known in the art.
  • pulse generator 3 depicts a functional block diagram of the gastrointestinal pulse generator according to the present invention.
  • pulse generator 3 is enclosed by hermetic enclosure 40 to the electronics and battery while the device is implanted.
  • Hermetic enclosure may consist of any suitable construction.
  • Pulse generator 3 couples with two sets of leads 4, 5 which are, in turn, coupled to the stomach 10.
  • the first set of leads 4 transmits stimulation pulses from pulse generator 3 to the stomach.
  • the second set of leads 5 provide sensing of the gastroelectrical activity of the stomach 10 to the pulse generator 3.
  • the stimulating leads and sensing leads are separate leads, the present invention may also be employed using a combination of lead which both sense and stimulate.
  • the sensing leads 4 are coupled into a slow wave detection circuit 41.
  • Slow wave detection circuit 41 includes a band pass amplifier, a slew rate converter and two threshold detectors. Essentially, such a slow wave detection circuit 41 is similar to those used in a cardiac pacemaker but with several important characteristics.
  • the band pass amplifier has a much lower center frequency, preferably on the order of 0.3HZ when used in the stomach. Of course, the present invention may be used in each of the various organs along the GI tract so that the center frequency may be varied accordingly.
  • the slew rate converter operates in a manner well known in the art and generates a signal corresponding to the slew rate of the sensed electrogastrogram.
  • the threshold detectors operates in a manner well known in the art and generate output signals when the sensed input signal is above a threshold level.
  • One threshold detector corresponds to the peak to peak amplitude of the sensed electrogastrogram.
  • the second threshold detector corresponds to the sensed slew rate.
  • the slow wave detection circuit 41 must be able to detect input signals between approximately 30 microvolts and 10 millivolts which have a slew rate between 100 microvolts per/second up to 10 volts per/second with a typical value of
  • the slew rate detector may also include an interference detector specially designed to detect continuous interference, especially at any of the various mains frequencies of power distribution (e.g. 16-400 Hz) so that false sensing is avoided.
  • a second sense amplifier may be provided having a bandpass in the range of expected power field variations in various frequencies of power distribution(e.g. 16-400 Hz). At every cycle the presence of interference is detected.
  • the time interval between two detections is measured and if this time interval corresponds to any of the main frequencies of power distribution which is preprogrammed, then this detection is labeled as interference and the detection on the other amplifier will be simultaneously labeled also as interference detection and not as a valid slow wave.
  • the band pass amplifier in the detection circuit 41 should be blanked for a period after a sensed event has been received by the microprocessor 46 or just before and during a stimulation pulse is emitted by output stage discussed below. Blanking may be accomplished through either a blanking switch which disconnects the amplifier from the electrodes or through a program performed in the microprocessor.
  • the microprocessor 46 should also ignore sensed output signals during a period after a sensed or paced event.
  • the blanking period for slow wave detection is on the order of between 0.5 to 4.0 seconds. Generally speaking, the blanking period decreases with increasing slow wave frequency.
  • the blanking period algorithm is controlled by the microprocessor.
  • the blanking period algorithm operates such that when the slow wave interval is shortened the blanking period is also shortened. This shortening may be performed in any manner, for example, in a linear fashion or in some other more complex monotonous fashion.
  • the microprocessor 46 is able to receive slow wave detection signals, which will not restart the pulse generator timing circuit, but will instead be interpreted as interference by the microprocessor 46.
  • This timing window may be up to seven seconds in duration after the sensed or paced event, preferably it is 100 milliseconds.
  • the combined blanking period and interference detection windows are shortened. Shortening may occur in any manner desired, i.e. in a linear fashion between a preset high or a preset low value or along a non-linear manner. The shortening of the combined blanking and interference detection interval will not occur once the combined blanking and interference detection window reaches a programmed value, such as 2.5 s.
  • This combined blanking window may also be programmed to be turned off such that it does not change in response to sensed physiologic signals. In all circumstances, however, the interference detection window remains equal to at least 100 ms.
  • the rationale is that the typical main frequencies of power distribution are 50 Hz, 60 Hz, 400 Hz and 16.33 Hz.
  • the lower harmonic for 1633 Hz is 8 Hz which corresponds to an interval of 125 ms.
  • the exact length of time for each period may be programmed by the physician.
  • each of the periods may be further made to be automatically adjusted based on the sensed electrical activity.
  • blanking switch 42 couples sensing electrodes 4 to amplifier 45 to detect high frequency spike activity.
  • the operation of blanking switch 42 causes the amplifier 45 to be connected to the sensing electrodes 4 once an intrinsic deflection or slow wave has been detected by slow wave detection circuit 41 or a stimulus has been emitted by output stage 47. Preferably, this occurs after a short delay.
  • Blanking switch 42 is closed between 0.5 to 2 seconds after these events and opens roughly 5 to 7 seconds later or at approximately 30% of the intrinsic event interval. As seen, the switch is controlled via the line 46e-42e.
  • the detection circuit for the high frequency spike activity detector consists of a bandpass amplifier having the center frequency at approximately 300 Hz. As discussed above, however, the center frequency will vary for different organs.
  • the amplifier is followed by two threshold detectors, the first detector detects peak to peak amplitude while the second detector detects slew rate. Both detectors are coupled using a logical AND configuration.
  • the detector pulses are counted, and the interval between pulses is measured. If the interval corresponds to the intervals of the mains frequencies of power distribution or any of their harmonies, i.e. 20 ms or 10 ms, they are rejected. If the number of pulses exceeds a pre-programmed value, then a contraction is indicated.
  • the counter is provided to store in the memory the time of occurrence of the contraction.
  • the number of pulses corresponding to each contraction may be counted and tallied to determine the strength of the contractions.
  • 3-5 pulses correspond to a weak contraction; 6-8 pulses correspond to a moderate contraction; 9 or more pulses correspond to a strong contraction.
  • 3-5 pulses correspond to a weak contraction; 6-8 pulses correspond to a moderate contraction; 9 or more pulses correspond to a strong contraction.
  • Each of these values may be programmed and the exact number of pulses will vary due to the implementation.
  • an AC current generator 43 is Also coupled to the sensing electrodes 4 .
  • This AC current generator 43 is part of a plethysmorgraphy circuit.
  • the plethysmography circuit is present to provide a means for sensing mechanical activity of the underlying tissue. That is, whereas the spike activity in the electrogastrogram may be used to sense contraction, the contraction may also be sensed using the plethysmography circuit.
  • Plethsmography circuit is comprised from AC current generator 43, amplifier, modulator and ADC converter 44 as well as a portion of the microprocessor 46.
  • the AC current generator 43 is switched on via signal from microprocessor 46 once a slow wave is detected or a pacing stimulus is emitted.
  • the AC current generator 43 amplitude and frequency are programmable via microprocessor 46.
  • the frequency should be such it is not detected by amplifiers 41, 45, e.g. ,1 kHz. If synchronous detection by amplifier 41 occurs at the end of the blanking period, then the amplitude and/or the frequency of the AC current generator 43 is adjusted by the microprocessor 46 to avoid subsequent detection of the generated AC current.
  • the amplifier, the modulator and ADC converter 44 the AC voltage caused by the injection of AC current generator 43 is amplified and demodulated and converted in order to detect impedance changes caused by contractions of the underlying tissue.
  • the ADC converter digitizes the amplitude of the demodulated signal.
  • the digitized signal is transmitted via line 44c-46h to the microprocessor 46.
  • the microprocessor 46 analyzes the signal pattern by comparing it with one or more templates to identify it as a contraction as well as to reject interference or signals generated by postural changes or vomiting. This template comparison is done synchronously to the detection of the slow wave.
  • Line 46i-44d is used to control the amplifier and ADC from the microprocessor 46.
  • the microprocessor 46 handles all timings and data storage of the pulse generator and may be of any suitable design. In the preferred embodiment, a microprocessor 46 such as that used in the Thera I series of Medtronic pacemakers is used. The description of the microprocessor 46 function is described in the section below which details the operation of the algorithm used in the present invention.
  • Stimulation pulses are generated by the output stage 47.
  • the output stage 47 generates pulse trains. It should be understood many types of pulse trains or stimulation pulses may be used including constant current or constant voltage outputs, or a mixture of both.
  • the output pulses are transported to the gastrointestinal tissue via medical electrical leads 5 and thus to the stomach.
  • FIG. 5 shows an electrogastrogram of the stomach in a human. As seen, this intrinsic gastroelectric activity has two distinct components.
  • the first component 501 is a low-frequency, rhythmic depolarization termed slow waves.
  • a high frequency spike activity 502 which corresponds to mechanical contractions of the organ.
  • slow waves are regular, omnipresent depolarizations at 3 cycles/min. (0.05 Hz) that commence high on the greater curvature of the stomach, in the region referred to as the pacemaker region, and propagate aborally, as depicted in FIG. 2.
  • the normal frequency range for the slow wave in the stomach is between 2.7 - 3.4 bpm. In clinical situations this value may vary anywhere between 1-15 bpm.
  • High frequency slow wave activity (called tachygastria) does not permit contraction of the stomach readily and may even results in a gastroparesis.
  • bradygastria In the presence of excessively slow or even absent slow waves (called bradygastria) motility is reduced.
  • Migratory Motor The spike activity occurs incidentally for a few of the slow waves while the patient is in a fasting or non-eating condition. This is termed Migratory Motor
  • MMC II changes into MMC II.
  • MMC III spike activity component
  • FIG. 6 depicts electrogastrogram tracings of a stomach illustrating the operation of the device to treat abnormal electrogastric activity.
  • the stomach typically has periodic slow waves which occur at an intrinsic rate of 3 beats per minute or approximately 20 seconds apart. These intrinsic slow waves typically occur at a relatively fixed rate.
  • these fixed, periodic slow waves are shown as waves 601, 602 and, 603.
  • each slow wave features a high frequency spike activity, such 601-1 and 603-3. This high frequency spike activity is a sign of contraction by the muscle, indicating normal motility.
  • the pulse generator features two sensor.
  • the first sensor senses slow waves, like 601, 602 and 603.
  • the second sensor senses spike activity, like 601-1 and 603-3.
  • the pulse generator further delivers stimulation pulse trains to the gastrointestinal tract at a period of time after slow waves have been sensed by the first sensor. If, however, the second sensor senses intrinsic spike activity between the frequency of 100 - 5000 Hz, then the delivery of stimulation pulse trains to the gastrointestinal tract is inhibited.
  • the present invention provides electrical stimulation to the gastrointestinal tract at all times except when normal gastric activity is detected.
  • the slow wave rate interval has timed out and a pulse train consisting of a slow wave escape stimulation is delivered at 605.
  • 605 is a pulse train with two components, a low frequency high amplitude front followed by a lower amplitude higher frequency end.
  • FIG. 7 is a flowchart of the present invention.
  • FIG. 7 is a flow chart of the present invention.
  • the invention generally requires sensing of the two distinct waves or electrical signals in the EGG, low frequency slow waves and high frequency spike activity.
  • slow waves are sensed in the frequency range of approximately 0.005 - 5 Hz while spike activity is sensed in the range of approximately 100 - 5000 Hz.
  • step 7-1 slow waves are sensed. If no slow waves are sensed then the device proceeds to step 7-2 with the lower rate timer operating. As seen, if the lower rate limit timer is not timed out, then the device resets and continues looping between step 7-1 and step 7-2.
  • slow wave electrical stimulation is delivered to normalize the slow waves in the stomach which have been found to be an effective treatment for the symptoms of gastroparesis, e.g. nausea or vomiting.
  • Slow wave electrical stimulation may comprise either a single pulse or a series of pulses delivered at a frequency of 10
  • step 7-1 If a low frequency slow wave is sensed at step 7-1, however, then the device proceeds to determine whether any spike activity is sensed. Once the slow wave electrical stimulation is delivered the device proceeds to step 7-5 and delivers burst electrical stimulation. The burst electrical stimulation is delivered at step 7-5 in order to elicit or cause a contraction of the stomach. If spike activity is sensed, then the device proceeds to step 7-6, and determines whether the number of spikes is lower than a selected value.
  • step 7-5 the device delivers burst electrical stimulation to thereby cause a contraction of the stomach. If, however, sufficient number of spikes are sensed in step 7-6, then the device is reset and proceeds again through the loop beginning at step 7-1.
  • the device continuously monitors first, whether slow waves occur in the stomach and, if they are not occurring, delivers slow wave electrical stimulation followed by burst electrical stimulation. If, however, slow waves are sensed then the device determines whether or not spike activity is following. If an insufficient amount of spike activity is following then burst electrical stimulation is delivered to thereby cause a contraction.
  • the device may be programmed to detect spike activity and count the number of spikes sensed associated to each corresponding slow wave. This number of spikes corresponding to each slow wave and thus each contraction may be counted and tallied to determine or assess the strength of the contractions.
  • 3-5 spikes correspond to a weak contraction; 6-8 spikes correspond to a moderate contraction and 9 or more spikes correspond to a strong contraction.
  • Each of these values may be programmed and the exact number of spikes necessary to achieve the corresponding characterization of the contraction will vary due to the organ in which the device is used.
  • FIG. 8a depicts a pulse train used in the present invention.
  • the preferred pulse train 300 is emitted at a frequency of 30 Hz and has a duration of approximately 4 seconds, each pulse lasting 330 microseconds with an amplitude of 0.5 to 10 Volts or a current of between approximately 0.1 milliamps to 30 milliamps.
  • all of the stimulation may be programmed as well as the waveforms used and their phase.
  • FIG. 8b depicts an alternate pulse train which may be used with the present system.
  • Muscle stimulation burst 300 has essentially two section, first section 301 and second section 302. As seen, first section 301 has a smaller interpulse interval 304 within the burst, i.e. a higher frequency.
  • second section 302 has a relatively larger interpulse interval 304 within the burst, i.e. a relatively smaller frequency.
  • interpulse interval 304 and number of pulses in the first section may be selected by the physician.
  • the pulse waveform and amplitude 308 are the same for the remainder of the burst.
  • FIG. 8c depicts an alternate embodiment of a pulse train which may be used with the present system. As seen all parameters of the muscle stimulation burst 300 are the same as that described above with respect to FIG. 8a but for the amplitude of second section 302.
  • FIG. 8d depicts an alternate embodiment of a pulse train which may be used with the present system. As seen all parameters of the muscle stimulation burst 300 are the same as that described above with respect to FIG. 7 but for the amplitude of second section 302. In particular amplitude of each burst within second section 302 decreases.
  • FIG. 8e depicts an alternate embodiment of a pulse train which may be used with the present system.
  • burst 300 consists of a number of pulses 309.
  • the amplitude of each pulse 309 differs from the amplitude of each preceding and following pulse.
  • the interpulse interval between each pulse 309 is different. None of 320, 321, 322, 323, 324, 325 or 326 are equal to another.
  • Each of the various parameters, such as amplitude 308 and the rate of change of amplitude 308, synchronization delay 305 and interpulse intervals 320, 321, 322, 323, 324, 325 and 326 are programmed on a patient by patient basis so as to attain the most efficient stimulation while minimizing energy expenditure.
  • each of the above identified various parameters including frequency, amplitude, rate of change of amplitude, rate of change of interpulse interval, etc. may be programmed on a patient by patient basis so as to attain the most efficient stimulation while minimizing energy expenditure. From a system component viewpoint the system operates as follows. Upon the detection of a sensed slow wave or a principal stimulated event, the escape timer is reset and starts counting. A stimulation pulse or pulse train will be emitted at the end of the timing out of the escape timer.
  • a slow wave is detected after the end of the refractory period and before the escape interval times out, then the stimulation is inhibited and the counters are reset. This occurs in the inhibited mode, similar to VVI cardiac pacing. If, however, ratio escape interval to a stimulation interval is programmed, e.g., a value of 5 and the escape interval is 20 seconds, then stimulation pulses would be emitted every 4 seconds but stimulation during the refractory period will not reset the escape timer. If a contraction occurs, spike activity is seen in the electrogastrogram. To avoid saturation of the slow wave detection circuit 41 of spike activity, the amplifier is connected via a switch to the connecting electrodes.
  • This switch connects the amplifier to the sensing electrodes once an intrinsic deflection has been detected or a stimulus has been emitted. This could occur after a short delay.
  • the switch is closed roughly 0.5 - 2 seconds after the above events, and closes roughly 5 - 7 seconds later or at 30% of the intrinsic interval.
  • the switch is controlled via the line 46e-42e from the microprocessor 46. Each confirmation of a detected spike and the interval between two detections is stored in the memory of the microprocessor 46. When the blanking switch is opened, the microprocessor 46 calculates the number of spikes sensed.
  • the microprocessor 46 confirms a mechanical contraction has been sensed. This event, with its time of occurrence, is stored in memory.
  • Plethysmorgraphy may be used to validate the high frequency spike activity detection or programmed on if the electrodes are at locations where no high frequency spike activity may be sensed.
  • the operation of the plethysmorgraphy circuit is as follows.
  • the current generator injects an AC current between 100 microamps and 10 milliamps at a frequency of 1 kilohertz to 20 kilohertz between the two sensing electrodes or a sensing electrode and the implantable pulse generator can, as is well known in the art.
  • the current generator is switched on a few seconds (1-3 seconds) after the detection of a slow wave or after the emission of a principle stimulus.
  • the current generator is then switched off roughly 7 to 10 seconds later after the detected event.
  • the amplifier could have a front end switch to avoid saturation by stimulation or the slow wave.
  • the operation of the switch and timing is identical to that discussed above with regards to the blanking switch, but the total interval the switch is left open is longer, 7-10 seconds, due to the electrical mechanical delay of the underlying tissue.
  • sampling the impedance wave form it could be made to be either synchronous or asynchronous to the AC current source.
  • the sequential digitized signals sensed using the sensing electrodes are compared with templates collected and stored in the microprocessor 46.
  • the templates are collected during the migrating motor complex phase at which no spike activity is detected.
  • Such a phase is created during a learning period of the pulse generator so that the templates may be collected and stored.
  • the migrating motor complex phase includes postural changes, coughing and perhaps even hurling.
  • the learning period of the pulse generator should also include periods when the patient is prandal and when spike activity is detected.
  • a template corresponding or useful to identifying vomiting may be collected as follows. If the amplitude of the measured signal exceeds the highest value during the migrating motor complex phase of the learning period of the pulse generator and no vomiting occurred during that time, then the sensed signal should be concluded as being or corresponding to vomiting
  • FIG. 9 depicts the specific steps used in the present invention to determine contraction or vomiting or other changes in the stomach using plethsmography.
  • the voltage resulting from the injection of AC current is sampled.
  • the AC voltage profile is generated over time.
  • the generated AC voltage profile is compared to stored templates to reach a probable diagnosis. Examples of such stored templates are further shown, e.g. the change in AC voltage due to a normal contraction, vomiting or a postural change.
  • the probable diagnosis is compared against whether any spike activity is detected.
  • an output of whether the diagnosis is confirmed is provided.
  • the electrode tissue impedance is measured. Such a scheme is well known in the art as seen in the Medtronic Itrel III Nerve Stimulator. If the electrode tissue impedance increases significantly between two measurements or if the electrode tissue impedance exceeds a preset level, then one may conclude the stimulation will be ineffective and an electrode may be dislodged. From that time forward the stimulator is switched to an off position so that no output signals are sent.
  • FIG. 10 depicts the electrical stimulation delivered in the normal mode of the device.
  • Electrical stimulation preferably consists of a pulse train delivered at a rate of between 7 - 27 bpm with 12 bpm preferred.
  • the pulse train preferred consists of two pulses, the pulse having an amplitude A, a pulsewidth PW and an inter pulse interval II. II may be anywhere between 6 - 600 ms in length with 60 ms preferred, A is between 1 - 50 milliamps with 5 milliamps preferred and pulsewidth is between 3 - 1000 microsecs with 330 microsecs preferred.
  • the pulse train consisting of two pulses is preferred, any number of pulses between 1 - 100 may be used.

Abstract

Apparatus for providing electrical stimulation of the gastrointestinal tract in absence of normal peristaltic contractions. An implantable pulse generator is coupled to the gastric system through one or more medical electrical leads. The leads should couple to the circular layer of the stomach. The apparatus comprises sensors for sensing gastric electrical activity, and in particular, whether peristaltic contractions are occurring. A first sensor low frequency gastrointestinal electrical activity between the frequency of 0.0017-0.25 Hz and a second sensor senses intrinsic gastrointestinal electrical activity between the frequency of 100-300 Hz, which occurs upon normal peristaltic contractions. The second sensor only senses for a preset period after low frequency gastrointestinal electrical activity has been sensed by the first sensor. The pulse generator delivers stimulation pulse trains to the gastrointestinal tract at a period of time after low frequency gastrointestinal electrical activity has been sensed by the first sensor. If however, the second sensor senses intrinsic gastrointestinal electrical activity between the frequency of 100-300 Hz, then the delivery of stimulation pulse trains to the gastrointestinal tract is inhibited.

Description

METHOD AND APPARATUS FORELECTRICAL STIMULATION OFTHE GASTROINTESTINAL TRACT
FIELD OF THE INVENTION The invention relates to treatment of gastrointestinal disorders using a method and apparatus for providing electrical stimulation of the gastrointestinal tract.
BACKGROUND OF THE INVENTION The gastrointestinal tract is responsible for an essential step in the digestive process, the reception of nutrition in the human body. An important element of the digestive process is peristalsis, the coordinated and self-regulated motor activity of the intestinal tract. Peristalsis is accomplished through a coordinated combination of electrical, chemical, neurological and hormonal mediation, as well as possibly other, as yet unknown, mechanisms. Many diseases and maladies can affect the motor activity of the gastrointestinal tract, causing malfunction of the digestive process. Such diseases include diabetes mellitus, scleroderma, intestinal pseudo-obstruction, ileus, and gastroparesis.
Gastroparesis, for example, is a chronic gastric motility disorder in which there is delayed gastric emptying of solids and/or liquids. Symptoms of gastroparesis may range from early satiety and nausea in mild cases to chronic vomiting, dehydration, and nutritional compromise in severe cases. Diagnosis of gastroparesis is based on demonstration of delayed gastric emptying of a radio- labeled solid meal in the absence of mechanical obstruction. Gastroparesis may occur for a number of reasons. Approximately one third of patients with gastroparesis, however, have no identifiable underlying cause (often called idiopathic gastroparesis). Management of gastroparesis involves four areas: (1) prokinetic drugs, (2) antiemetic drugs, (3) nutritional support, and (4) surgical therapy (in a very small subset of patients.) Gastroparesis is often a chronic, relapsing condition; 80% of patients require maintenance antiemetic and prokinetic therapy and 20%> require long-term nutritional supplementation. Other maladies such as tachygastria or bradygastria can also hinder coordinated muscular motor activity of the gastrointestinal tract, possibly resulting in either stasis or nausea or vomiting or a combination thereof.
The undesired effect of these conditions is a reduced ability or complete failure to efficiently propel intestinal contents down the digestive tract. This results in malassimilation of liquid or food by the absorbing mucosa of the intestinal tract. If this condition is not corrected, malnutrition or even starvation may occur. Moreover nausea or vomiting or both may also occur. Whereas some of these disease states can be corrected by medication or by simple surgery, in most cases treatment with drugs is not adequately effective, and surgery often has intolerable physiologic effects on the body.
Presently, however, there is no practically effective device or system to stimulator intelligently alter the muscular contractions of smooth muscle and the gastrointestinal tract in particular. Therefore, there is a need in the art for a system and method to properly stimulate the gastrointestinal tract to thereby treat ineffective or absent electrical muscular activity of the gastrointestinal tract.
SUMMARY OF THE INVENTION It is an object of the invention to provide a method and apparatus for treating patients having dysfunctional gastrointestinal muscle or disorders of smooth muscles elsewhere in the body.
This and other objects are provided by one or more of the embodiments described below. The present invention is a method and apparatus for providing electrical stimulation of the gastrointestinal tract. The apparatus features an implantable pulse generator which may be coupled to the gastric system through one or more medical electrical leads. In the preferred embodiment the leads couple to the circular layer of the stomach. The pulse generator preferably features sensors for sensing gastric electrical activity, and in particular, whether peristaltic contractions as occurring. In particular two sensors are featured. The first sensor senses low frequency gastrointestinal electrical activity between the frequency of approximately 0.005 Hz - 5 Hz ("slow waves") and the second sensor senses intrinsic gastrointestinal electrical activity between the frequency of approximately 100 - 5000 Hz ("spike activity") which occurs upon normal peristaltic contractions and immediately follows a slow wave. The second sensor only senses for a preset period after a slow waves has been sensed by the first sensor. The pulse generator further delivers stimulation pulse trains to the gastrointestinal tract at a period of time after slow waves have been sensed by the first sensor. If, however, the second sensor senses a sufficient amount of spike activity, then the delivery of stimulation pulse trains to the gastrointestinal tract is inhibited. In such a manner the present invention detects the occurrence of normal peristaltic contractions and further provides electrical stimulation to the gastrointestinal tract if such normal peristaltic contractions are not detected.
BRIEF DESCRIPTION OF THE DRAWINGS The above-described and other aspects of the present invention may be better understood and appreciated with reference to a detailed description of a specific embodiment of the invention, when read in conjunction with the accompanying drawings, wherein:
FIG. 1 depicts the apparatus implanted within a patient. FIG. 2 depicts a detailed view of the stomach muscle showing the electrode of the lead implanted.
FIG. 3 depicts a plan view of a lead used with the apparatus. FIG. 4 is a functional block diagram of the pulse generator. FIG. 5 is an electrogastrogram of the gastrointestinal system. FIG. 6 is an electrogastrogram illustrating an arrhythmia and the response of the apparatus.
FIG. 7 is a flowchart depicting the operation of the system. FIG. 8a-8e depict various pulse trains which may be emitted by the present system.
FIG. 9 depicts the steps used in the present invention to determine contraction or vomiting or other changes in the stomach using plethsmography. FIG. 10 depicts the electrical stimulation delivered in the normal mode of the device.
The FIGS, are not necessarily to scale.
DETAILED DESCRIPTION OF THE INVENTION
FIG. 1 shows a system 1 implanted in a patient 2. As seen, the system 1 comprises an implantable pulse generator 3 featuring two sets of leads 4, 5 which are coupled to the stomach 10. The first set of leads 4 provide stimulation to the stomach. The second set of leads 5 provide sensing of the gastroelectrical activity of the stomach 10 to the pulse generator 3. In the preferred embodiment, the pulse generator
3 is implanted within the patient 2. As such, the implantable pulse generator 3 features a hermetic enclosure, as is well known in the art. The leads used for both the first set 4 and the second set 5 may be any acceptable lead. In the preferred embodiment, the preferred leads are Medtronic Model No. 4300 intramuscular lead. Of course, other configurations of leads or lead systems may be used, including the use of from only a single lead, a single set of leads (i.e. two), or even the use of three or more sets of leads. Moreover, although shown as being coupled to the stomach it must be understood the present invention may be used along or on any of the other structures and organs along the gastrointestinal tract, including the colon, small intestine, stomach or even the esophagus.
The first set of leads 4 are stimulation leads which conduct stimulation pulses from the pulse generator 3 to the stomach 10. First set of leads 4 are preferably implanted through the serosa at the area within the transition of the corpus and the antrum on the great curvature. Of course, other locations for first set of leads 4 may be used, such as in the fundus, caudud corpus as well as the orad or terminal antrum.
The second set of leads 5 are sensing leads which conduct any gastroelectrical activities sensed in the stomach 10 to the pulse generator 3. Preferably the second set of leads 5 are positioned distally in the mid antrum also along the great curvature, although these leads may also be positioned in other locations. FIG. 2 details the preferred positioning of an electrode of a lead within the various layers of the stomach. As seen, the stomach 10 has essentially seven layers of tissue. In the preferred embodiment, the electrode of each lead is positioned into the layers of the stomach muscle as shown. That is, the electrode is positioned such that it intersects both the longitudinal and circular layers. This is believed important by the inventor because in such a manner the electrode is able to also intersect the enteric nervous system of the stomach and be in close contact with the cells of Cajal. This is believed important as research has shown that intramuscular electrodes may effectively stimulate the stomach with less than one one-thousandths of the energy required for serosal electrodes. Of course, other types of electrodes or lead systems may be used, including those which contact only any one of each of the layers of the stomach organ, such as only the mucosa or only the serosa. Moreover, although in the preferred embodiment a pair of unipolar leads are used for stimulation and a second pair of unipolar leads are used for stimulation, other configurations of leads may be used, such as bipolar, tripolar, quadrapolar, as well as any other configuration suitable such as a unipolar lead and can. FIG. 3 depicts a plan view of the preferred embodiment lead 15 used in the present invention. As seen, the lead 15 essentially has three sections, connector section 16, body section 17 and fixation section 18. Connector section 16 includes a connector pin 22 to electrically couple the lead 15 into the pulse generator. Any connector pin 22 as well known in the art may be used. Body section 17 includes an electrical conductor 19 surrounded by an electrical insulator 20. In the preferred embodiment electrical conductor 19 is a platinum iridium alloy and electrical insulator 18 is silicone. Of course, other biocompatible materials may also be used. As seen, at the distal end of the body section 17 is an electrode 25. In the preferred embodiment, electrode 25 is a polished platinum iridium alloy. Of course, other materials may likewise be used, such as a porous platinized structure. In addition, the electrode 25 could further feature various pharmaceutical agents, such as dexamethasone sodium phosphate or beclomethasone phosphate in order to minimize the inflammatory response of the tissue to the implanted lead 15. Other agents such as antibiotics may also be used. Located distal to the electrode 25 is the fixation section 18. As seen, fixation section 18 has essentially two piece parts, a suture 26 which is in turn coupled to a needle 27. Needle 27 is preferably curved. In an alternate embodiment suture may feature a fixation coil as is well known in the art to cooperate with the body tissue after implantation to maintain the lead 15 in the position implanted. Of course, other fixation mechanisms may be used, such as fixation discs, as is well known in the art. FIG. 4 depicts a functional block diagram of the gastrointestinal pulse generator according to the present invention. As seen, pulse generator 3 is enclosed by hermetic enclosure 40 to the electronics and battery while the device is implanted. Hermetic enclosure may consist of any suitable construction. Pulse generator 3 couples with two sets of leads 4, 5 which are, in turn, coupled to the stomach 10. The first set of leads 4 transmits stimulation pulses from pulse generator 3 to the stomach.
The second set of leads 5 provide sensing of the gastroelectrical activity of the stomach 10 to the pulse generator 3. Although in the preferred embodiment the stimulating leads and sensing leads are separate leads, the present invention may also be employed using a combination of lead which both sense and stimulate. As seen, the sensing leads 4 are coupled into a slow wave detection circuit 41.
Slow wave detection circuit 41 includes a band pass amplifier, a slew rate converter and two threshold detectors. Essentially, such a slow wave detection circuit 41 is similar to those used in a cardiac pacemaker but with several important characteristics. First, the band pass amplifier has a much lower center frequency, preferably on the order of 0.3HZ when used in the stomach. Of course, the present invention may be used in each of the various organs along the GI tract so that the center frequency may be varied accordingly. The slew rate converter operates in a manner well known in the art and generates a signal corresponding to the slew rate of the sensed electrogastrogram. The threshold detectors operates in a manner well known in the art and generate output signals when the sensed input signal is above a threshold level.
One threshold detector corresponds to the peak to peak amplitude of the sensed electrogastrogram. The second threshold detector corresponds to the sensed slew rate.
Preferably, the slow wave detection circuit 41 must be able to detect input signals between approximately 30 microvolts and 10 millivolts which have a slew rate between 100 microvolts per/second up to 10 volts per/second with a typical value of
100 millivolts per second. Such a range may be achieved using multiple steps which are controlled by the microprocessor 46 via the input line 46b-41d. To detect the slow wave, both threshold detectors should be coupled using a logical AND configuration. Thus, a signal should then be sent via the output line 41c-46a to the microprocessor 46. The slew rate detector may also include an interference detector specially designed to detect continuous interference, especially at any of the various mains frequencies of power distribution (e.g. 16-400 Hz) so that false sensing is avoided. In an alternative embodiment a second sense amplifier may be provided having a bandpass in the range of expected power field variations in various frequencies of power distribution(e.g. 16-400 Hz). At every cycle the presence of interference is detected. The time interval between two detections is measured and if this time interval corresponds to any of the main frequencies of power distribution which is preprogrammed, then this detection is labeled as interference and the detection on the other amplifier will be simultaneously labeled also as interference detection and not as a valid slow wave. The band pass amplifier in the detection circuit 41 should be blanked for a period after a sensed event has been received by the microprocessor 46 or just before and during a stimulation pulse is emitted by output stage discussed below. Blanking may be accomplished through either a blanking switch which disconnects the amplifier from the electrodes or through a program performed in the microprocessor. The microprocessor 46 should also ignore sensed output signals during a period after a sensed or paced event. This is similar to a blanking circuit where sensed events during a blanking period do not affect the timing of the pulse generator. In the preferred embodiment, the blanking period for slow wave detection is on the order of between 0.5 to 4.0 seconds. Generally speaking, the blanking period decreases with increasing slow wave frequency. The blanking period algorithm is controlled by the microprocessor. The blanking period algorithm operates such that when the slow wave interval is shortened the blanking period is also shortened. This shortening may be performed in any manner, for example, in a linear fashion or in some other more complex monotonous fashion. After the blanking period, during a certain timing window, the microprocessor 46 is able to receive slow wave detection signals, which will not restart the pulse generator timing circuit, but will instead be interpreted as interference by the microprocessor 46. This timing window, interference detection timing window, may be up to seven seconds in duration after the sensed or paced event, preferably it is 100 milliseconds. To be precise, the combined blanking period and interference detection windows are shortened. Shortening may occur in any manner desired, i.e. in a linear fashion between a preset high or a preset low value or along a non-linear manner. The shortening of the combined blanking and interference detection interval will not occur once the combined blanking and interference detection window reaches a programmed value, such as 2.5 s. This combined blanking window may also be programmed to be turned off such that it does not change in response to sensed physiologic signals. In all circumstances, however, the interference detection window remains equal to at least 100 ms. For example, the rationale is that the typical main frequencies of power distribution are 50 Hz, 60 Hz, 400 Hz and 16.33 Hz. The lower harmonic for 1633 Hz is 8 Hz which corresponds to an interval of 125 ms. Of course the exact length of time for each period may be programmed by the physician. Moreover, each of the periods may be further made to be automatically adjusted based on the sensed electrical activity.
As seen in FIG. 4, blanking switch 42 couples sensing electrodes 4 to amplifier 45 to detect high frequency spike activity. The operation of blanking switch 42 causes the amplifier 45 to be connected to the sensing electrodes 4 once an intrinsic deflection or slow wave has been detected by slow wave detection circuit 41 or a stimulus has been emitted by output stage 47. Preferably, this occurs after a short delay. Blanking switch 42 is closed between 0.5 to 2 seconds after these events and opens roughly 5 to 7 seconds later or at approximately 30% of the intrinsic event interval. As seen, the switch is controlled via the line 46e-42e.
The detection circuit for the high frequency spike activity detector consists of a bandpass amplifier having the center frequency at approximately 300 Hz. As discussed above, however, the center frequency will vary for different organs. The amplifier is followed by two threshold detectors, the first detector detects peak to peak amplitude while the second detector detects slew rate. Both detectors are coupled using a logical AND configuration. The detector pulses are counted, and the interval between pulses is measured. If the interval corresponds to the intervals of the mains frequencies of power distribution or any of their harmonies, i.e. 20 ms or 10 ms, they are rejected. If the number of pulses exceeds a pre-programmed value, then a contraction is indicated. The counter is provided to store in the memory the time of occurrence of the contraction. The number of pulses corresponding to each contraction may be counted and tallied to determine the strength of the contractions. In the present embodiment 3-5 pulses correspond to a weak contraction; 6-8 pulses correspond to a moderate contraction; 9 or more pulses correspond to a strong contraction. Each of these values, of course, may be programmed and the exact number of pulses will vary due to the implementation.
Also coupled to the sensing electrodes 4 is an AC current generator 43. This AC current generator 43 is part of a plethysmorgraphy circuit. Overall, the plethysmography circuit is present to provide a means for sensing mechanical activity of the underlying tissue. That is, whereas the spike activity in the electrogastrogram may be used to sense contraction, the contraction may also be sensed using the plethysmography circuit. Plethsmography circuit is comprised from AC current generator 43, amplifier, modulator and ADC converter 44 as well as a portion of the microprocessor 46. The AC current generator 43 is switched on via signal from microprocessor 46 once a slow wave is detected or a pacing stimulus is emitted. It is switched off roughly 10 seconds after being switched on also from the same line or signal from the microprocessor 46. The AC current generator 43 amplitude and frequency are programmable via microprocessor 46. The frequency should be such it is not detected by amplifiers 41, 45, e.g. ,1 kHz. If synchronous detection by amplifier 41 occurs at the end of the blanking period, then the amplitude and/or the frequency of the AC current generator 43 is adjusted by the microprocessor 46 to avoid subsequent detection of the generated AC current.
Turning now to the amplifier, the modulator and ADC converter 44, the AC voltage caused by the injection of AC current generator 43 is amplified and demodulated and converted in order to detect impedance changes caused by contractions of the underlying tissue. The ADC converter digitizes the amplitude of the demodulated signal. The digitized signal is transmitted via line 44c-46h to the microprocessor 46. The microprocessor 46 analyzes the signal pattern by comparing it with one or more templates to identify it as a contraction as well as to reject interference or signals generated by postural changes or vomiting. This template comparison is done synchronously to the detection of the slow wave. Line 46i-44d is used to control the amplifier and ADC from the microprocessor 46.
The microprocessor 46 handles all timings and data storage of the pulse generator and may be of any suitable design. In the preferred embodiment, a microprocessor 46 such as that used in the Thera I series of Medtronic pacemakers is used. The description of the microprocessor 46 function is described in the section below which details the operation of the algorithm used in the present invention.
Stimulation pulses are generated by the output stage 47. In the preferred embodiment, the output stage 47 generates pulse trains. It should be understood many types of pulse trains or stimulation pulses may be used including constant current or constant voltage outputs, or a mixture of both. The output pulses are transported to the gastrointestinal tissue via medical electrical leads 5 and thus to the stomach.
Turning again to the output stage 47, when an output pulse is to be delivered, its amplitude, pulse width and duration and frequencies are controlled via lines 46j- 47a. If it is a burst of stimuli, the frequency and duration are controlled through the same line while a burst finished signal is sent to the microprocessor 46 via output line 47b-46k.
Programmability to the pulse generator 3 is achieved through receiver- demodulator 48 and transmitter 49. As seen, each of these devices is coupled to the microprocessor 46. The receiver-demodulator 48 and transmitter 49 are similar to those used in cardiac pacemakers. The basic parameter settings such as sensitivity (peak voltage or slew rate), refractory, blanking, output pulse amplitude, pulse width, escape interval and ratio, escape interval to a stimulation interval, are stored in the memory of the microprocessor 46. Default values are also stored. These values can be read from memory and sent to a receiver via the transmitter. FIG. 5 shows an electrogastrogram of the stomach in a human. As seen, this intrinsic gastroelectric activity has two distinct components. The first component 501 is a low-frequency, rhythmic depolarization termed slow waves. Superimposed on the slow wave is a high frequency spike activity 502 which corresponds to mechanical contractions of the organ. In the human stomach slow waves are regular, omnipresent depolarizations at 3 cycles/min. (0.05 Hz) that commence high on the greater curvature of the stomach, in the region referred to as the pacemaker region, and propagate aborally, as depicted in FIG. 2.
The normal frequency range for the slow wave in the stomach is between 2.7 - 3.4 bpm. In clinical situations this value may vary anywhere between 1-15 bpm. High frequency slow wave activity (called tachygastria) does not permit contraction of the stomach readily and may even results in a gastroparesis. In the presence of excessively slow or even absent slow waves (called bradygastria) motility is reduced.
Slow waves and the corresponding spike activity may become irregular or uncoupled or both, thereby preventing the appearance or organization of regular, normally propagated contractions that constitute normal motility. Contractions cannot occur without gastric electrical response activity which is in turn regulated by the electrical control activity. Any disruption in this delicate sequential order may lead to delayed gastric emptying. An example of such an occurrence is shown in complex 505.
The spike activity occurs incidentally for a few of the slow waves while the patient is in a fasting or non-eating condition. This is termed Migratory Motor
Complex phase I. Immediately prior to a meal, typically 30 mins, MMC I changes into MMC II. During this phase the number of slow waves having spike activity increases. Once the meal or eating has begun and up to 120 mins after the meal each further slow wave also has a spike activity component. This condition is called MMC III.
As seen in this complex a slow wave 510 occurs which is not followed by any high frequency spike activity. The absence of such activity indicates there is no longer any peristaltic contraction which will occurs, i.e. gastric emptying is delayed. FIG. 6 depicts electrogastrogram tracings of a stomach illustrating the operation of the device to treat abnormal electrogastric activity. As seen, the stomach typically has periodic slow waves which occur at an intrinsic rate of 3 beats per minute or approximately 20 seconds apart. These intrinsic slow waves typically occur at a relatively fixed rate. Here, these fixed, periodic slow waves are shown as waves 601, 602 and, 603. In a normal electrogastrogram taken during a meal, each slow wave features a high frequency spike activity, such 601-1 and 603-3. This high frequency spike activity is a sign of contraction by the muscle, indicating normal motility.
As seen at slow wave 602, however, no high frequency spike activity is present. This indicates a lack of peristaltic waves in the stomach and thus diminished motility. As discussed above, the present invention detects such diminished motility and delivers electrical stimulation. In particular, the pulse generator features two sensor. The first sensor senses slow waves, like 601, 602 and 603. The second sensor senses spike activity, like 601-1 and 603-3. The pulse generator further delivers stimulation pulse trains to the gastrointestinal tract at a period of time after slow waves have been sensed by the first sensor. If, however, the second sensor senses intrinsic spike activity between the frequency of 100 - 5000 Hz, then the delivery of stimulation pulse trains to the gastrointestinal tract is inhibited. In such a manner the present invention provides electrical stimulation to the gastrointestinal tract at all times except when normal gastric activity is detected. At 604 the slow wave rate interval has timed out and a pulse train consisting of a slow wave escape stimulation is delivered at 605. As seen in this illustration 605 is a pulse train with two components, a low frequency high amplitude front followed by a lower amplitude higher frequency end.
FIG. 7 is a flowchart of the present invention. FIG. 7 is a flow chart of the present invention. As seen, in operation, the invention generally requires sensing of the two distinct waves or electrical signals in the EGG, low frequency slow waves and high frequency spike activity. As discussed above, slow waves are sensed in the frequency range of approximately 0.005 - 5 Hz while spike activity is sensed in the range of approximately 100 - 5000 Hz. At step 7-1 slow waves are sensed. If no slow waves are sensed then the device proceeds to step 7-2 with the lower rate timer operating. As seen, if the lower rate limit timer is not timed out, then the device resets and continues looping between step 7-1 and step 7-2. If the lower rate timers is timed out then the device proceeds to step 7-4 and delivers slow wave electrical stimulation. As discussed above, slow wave electrical stimulation is delivered to normalize the slow waves in the stomach which have been found to be an effective treatment for the symptoms of gastroparesis, e.g. nausea or vomiting. Slow wave electrical stimulation may comprise either a single pulse or a series of pulses delivered at a frequency of 10
- 100 Hz having an amplitude of 3 V and a pulse width of 330 ms. If a low frequency slow wave is sensed at step 7-1, however, then the device proceeds to determine whether any spike activity is sensed. Once the slow wave electrical stimulation is delivered the device proceeds to step 7-5 and delivers burst electrical stimulation. The burst electrical stimulation is delivered at step 7-5 in order to elicit or cause a contraction of the stomach. If spike activity is sensed, then the device proceeds to step 7-6, and determines whether the number of spikes is lower than a selected value. If the number of spikes is lower than the selected value, then an adequate contraction of the stomach is deemed not to have occurred and the device proceeds to step 7-5 where it delivers burst electrical stimulation to thereby cause a contraction of the stomach. If, however, sufficient number of spikes are sensed in step 7-6, then the device is reset and proceeds again through the loop beginning at step 7-1. Through this algorithm it is thus seen that the device continuously monitors first, whether slow waves occur in the stomach and, if they are not occurring, delivers slow wave electrical stimulation followed by burst electrical stimulation. If, however, slow waves are sensed then the device determines whether or not spike activity is following. If an insufficient amount of spike activity is following then burst electrical stimulation is delivered to thereby cause a contraction. If sufficient high frequency spike activity is occurring then the device resets itself and again senses for slow waves. For example, as discussed above, the device may be programmed to detect spike activity and count the number of spikes sensed associated to each corresponding slow wave. This number of spikes corresponding to each slow wave and thus each contraction may be counted and tallied to determine or assess the strength of the contractions. In the preferred embodiment 3-5 spikes correspond to a weak contraction; 6-8 spikes correspond to a moderate contraction and 9 or more spikes correspond to a strong contraction. Each of these values, of course, may be programmed and the exact number of spikes necessary to achieve the corresponding characterization of the contraction will vary due to the organ in which the device is used.
FIG. 8a depicts a pulse train used in the present invention. As seen, the preferred pulse train 300 is emitted at a frequency of 30 Hz and has a duration of approximately 4 seconds, each pulse lasting 330 microseconds with an amplitude of 0.5 to 10 Volts or a current of between approximately 0.1 milliamps to 30 milliamps. In an alternative embodiment all of the stimulation may be programmed as well as the waveforms used and their phase. FIG. 8b depicts an alternate pulse train which may be used with the present system. Muscle stimulation burst 300 has essentially two section, first section 301 and second section 302. As seen, first section 301 has a smaller interpulse interval 304 within the burst, i.e. a higher frequency. In comparison second section 302 has a relatively larger interpulse interval 304 within the burst, i.e. a relatively smaller frequency. In the preferred embodiment interpulse interval 304 and number of pulses in the first section may be selected by the physician. The pulse waveform and amplitude 308 are the same for the remainder of the burst.
FIG. 8c depicts an alternate embodiment of a pulse train which may be used with the present system. As seen all parameters of the muscle stimulation burst 300 are the same as that described above with respect to FIG. 8a but for the amplitude of second section 302.
FIG. 8d depicts an alternate embodiment of a pulse train which may be used with the present system. As seen all parameters of the muscle stimulation burst 300 are the same as that described above with respect to FIG. 7 but for the amplitude of second section 302. In particular amplitude of each burst within second section 302 decreases.
FIG. 8e depicts an alternate embodiment of a pulse train which may be used with the present system. As seen burst 300 consists of a number of pulses 309. The amplitude of each pulse 309 differs from the amplitude of each preceding and following pulse. In addition, the interpulse interval between each pulse 309 is different. None of 320, 321, 322, 323, 324, 325 or 326 are equal to another. Each of the various parameters, such as amplitude 308 and the rate of change of amplitude 308, synchronization delay 305 and interpulse intervals 320, 321, 322, 323, 324, 325 and 326 are programmed on a patient by patient basis so as to attain the most efficient stimulation while minimizing energy expenditure. Of course other unique waveforms of pulse trains may also be used, such as biphasic or poly phasic for example. In addition each of the above identified various parameters, including frequency, amplitude, rate of change of amplitude, rate of change of interpulse interval, etc. may be programmed on a patient by patient basis so as to attain the most efficient stimulation while minimizing energy expenditure. From a system component viewpoint the system operates as follows. Upon the detection of a sensed slow wave or a principal stimulated event, the escape timer is reset and starts counting. A stimulation pulse or pulse train will be emitted at the end of the timing out of the escape timer. If however, a slow wave is detected after the end of the refractory period and before the escape interval times out, then the stimulation is inhibited and the counters are reset. This occurs in the inhibited mode, similar to VVI cardiac pacing. If, however, ratio escape interval to a stimulation interval is programmed, e.g., a value of 5 and the escape interval is 20 seconds, then stimulation pulses would be emitted every 4 seconds but stimulation during the refractory period will not reset the escape timer. If a contraction occurs, spike activity is seen in the electrogastrogram. To avoid saturation of the slow wave detection circuit 41 of spike activity, the amplifier is connected via a switch to the connecting electrodes. This switch connects the amplifier to the sensing electrodes once an intrinsic deflection has been detected or a stimulus has been emitted. This could occur after a short delay. The switch is closed roughly 0.5 - 2 seconds after the above events, and closes roughly 5 - 7 seconds later or at 30% of the intrinsic interval. The switch is controlled via the line 46e-42e from the microprocessor 46. Each confirmation of a detected spike and the interval between two detections is stored in the memory of the microprocessor 46. When the blanking switch is opened, the microprocessor 46 calculates the number of spikes sensed. If the number of spikes sensed is above a set level, for example, 7, and if the interval between the spikes does not correspond to the interval of the main frequency or multiples from it, then the microprocessor 46 confirms a mechanical contraction has been sensed. This event, with its time of occurrence, is stored in memory.
Another method which may be used to detect mechanical contractions of the underlying tissue is plethysmorgraphy. Plethysmorgraphy may be used to validate the high frequency spike activity detection or programmed on if the electrodes are at locations where no high frequency spike activity may be sensed. The operation of the plethysmorgraphy circuit is as follows. The current generator injects an AC current between 100 microamps and 10 milliamps at a frequency of 1 kilohertz to 20 kilohertz between the two sensing electrodes or a sensing electrode and the implantable pulse generator can, as is well known in the art. The current generator is switched on a few seconds (1-3 seconds) after the detection of a slow wave or after the emission of a principle stimulus. The current generator is then switched off roughly 7 to 10 seconds later after the detected event. The amplifier could have a front end switch to avoid saturation by stimulation or the slow wave. The operation of the switch and timing is identical to that discussed above with regards to the blanking switch, but the total interval the switch is left open is longer, 7-10 seconds, due to the electrical mechanical delay of the underlying tissue. In case of sampling the impedance wave form, it could be made to be either synchronous or asynchronous to the AC current source. The sequential digitized signals sensed using the sensing electrodes are compared with templates collected and stored in the microprocessor 46. In the preferred embodiment, the templates are collected during the migrating motor complex phase at which no spike activity is detected. Such a phase is created during a learning period of the pulse generator so that the templates may be collected and stored. The migrating motor complex phase includes postural changes, coughing and perhaps even hurling. The learning period of the pulse generator should also include periods when the patient is prandal and when spike activity is detected. A template corresponding or useful to identifying vomiting may be collected as follows. If the amplitude of the measured signal exceeds the highest value during the migrating motor complex phase of the learning period of the pulse generator and no vomiting occurred during that time, then the sensed signal should be concluded as being or corresponding to vomiting
FIG. 9 depicts the specific steps used in the present invention to determine contraction or vomiting or other changes in the stomach using plethsmography. At 9- 1 the voltage resulting from the injection of AC current is sampled. At 9-2 the AC voltage profile is generated over time. At 9-3 the generated AC voltage profile is compared to stored templates to reach a probable diagnosis. Examples of such stored templates are further shown, e.g. the change in AC voltage due to a normal contraction, vomiting or a postural change. At 9-4 the probable diagnosis is compared against whether any spike activity is detected. At 9-5 an output of whether the diagnosis is confirmed is provided.
At each stimulus emitted or every preset numbers of stimuli, the electrode tissue impedance is measured. Such a scheme is well known in the art as seen in the Medtronic Itrel III Nerve Stimulator. If the electrode tissue impedance increases significantly between two measurements or if the electrode tissue impedance exceeds a preset level, then one may conclude the stimulation will be ineffective and an electrode may be dislodged. From that time forward the stimulator is switched to an off position so that no output signals are sent.
FIG. 10 depicts the electrical stimulation delivered in the normal mode of the device. Electrical stimulation preferably consists of a pulse train delivered at a rate of between 7 - 27 bpm with 12 bpm preferred. As seen, the pulse train preferred consists of two pulses, the pulse having an amplitude A, a pulsewidth PW and an inter pulse interval II. II may be anywhere between 6 - 600 ms in length with 60 ms preferred, A is between 1 - 50 milliamps with 5 milliamps preferred and pulsewidth is between 3 - 1000 microsecs with 330 microsecs preferred. Moreover, although the pulse train consisting of two pulses is preferred, any number of pulses between 1 - 100 may be used. As discussed above, the exact parameters selected depend not only on the organ to be stimulated but also upon the patient's physiology as well as on the preference of the physician attending. While the present invention has been described in detail with particular reference to a preferred embodiment, it will be understood variations and modifications can be effected within the scope of the following claims. Such modifications may include substituting elements or components which perform substantially the same function in substantially the same way to achieve substantially the same result for those described herein.

Claims

What is claimed is:
1. An apparatus for providing electrical stimulation to the gastrointestinal tract comprising: means for electrically coupling to the gastrointestinal tract; a first sensor for sensing intrinsic gastrointestinal electrical activity between the frequency of 100 - 300 Hz, the sensor coupled to the means for electrically coupling to the gastrointestinal tract, the sensor emitting an intrinsic gastrointestinal electrical activity signal upon the sensing of intrinsic gastrointestinal electrical activity; a pulse generator coupled to the means for electrically coupling to the gastrointestinal tract and the first sensor, the pulse generator emitting asynchronous stimulation pulse trains at a first rate, the pulse generator inhibiting the emission of asynchronous stimulation pulse trains al a first rate upon the emission of the intrinsic gastrointestinal electrical aclivHy signal by the first sensor.
2. The apparatus according to claim 1 wherein the stimulation pulse trains comprise a series of pulse trains emitted at a frequency of 30 Hz and a duration of approximately 4 seconds, each pulse lasting 330 microseconds with an amplitude of between approximately 0.5 to 1 Volts or a current of between approximately 0.1 milliamps to 30 milliamps.
3. The apparatus according to claim 1 wherein the pulse train having a first section and a second section, the first section having a first frequency, the second section having a second frequency.
4. The apparatus of claim 3 wherein the first frequency is greater than the second frequency,
5. The apparatus of claim 3 wherein the first frequency is less than the second frequency.
6. The apparatus of claim 3 wherein the first section has a first amplitude, the second section has a second amplitude.
7. The apparatus of claim 3 wherein Ihe first amplitude is less than the second amplitude.
8. An apparatus for providing electrical stimulation to the gastrointestinal tract comprising: means for electrically coupling to the gastrointestinal tract; a first sensor for sensing low frequency gastrointestinal electrical activity between the frequency of 0.017 - 0.25 Hz, the sensor coupled to the means for electrically coupling to the gastrointestinal tract, the sensor emitting a low frequency gastrointestinal electrical activity signal upon the sensing of low frequency gastrointestinal electrical activity; a second sensor for sensing intrinsic gastrointestinal electrical activity between the frequency of 100 - 300 Hz. the sensor coupled to ihe means for electrically coupling to the gastrointestinal tract and the first sensor, the second sensor emitting an intrinsic gastrointestinal electrical activity signal upon the sensing of intrinsic gastrointestinal electrical activity between the frequency of 100 - 300 Hz within a pre-set period after the emission of a low frequency gastrointestinal electrical activity signal by the first sensor; a pulse generator coupled lo the means for electrically coupling to the gastroinlestinal tract, the first sensor and the second sensor, the pulse generator emitting asynchronous stimulation pulse trains al a first rate, the pulse generator inhibiting the emission of asynclironous stimulation pulse trains at a first rate upon the emission of the intrinsic gastrointestinal electrical activity signal by the second sensor.
9. A method of electrically stimulating an organ comprising the steps of: sensing low frequency slow waves; determining whether the sensed low frequency slow waves a exceeds predetermined slow wave amount; delivering slow wave electrical stimulation if the sensed low frequency slow waves do not exceed the predetermined slow wave amount and delivering burst electrical stimulation; sensing high frequency spike activity; determining whether the sensed high frequency spike activity exceeds predetermined fast wave amount; and delivering burst electrical stimulation if the sensed high frequency spike activity is lower than the predetermined fast wave amount.
10. The method of electrically stimulating an organ of claim 9 wherein the slep of sensing low frequency slow waves comprises sensing gastrointestinal electrical activity between the frequency of approximately 0.017 - 0.25 Hz.
11. The method of electrically stimulating an organ of claim 9 wherein the step of sensing high frequency spike activity comprises sensing gastrointestinal electrical activity between the frequency of approximately 100 - 1000 Hz.
12. The method of electrically stimulating an organ of claim 9 wherein the step of sensing high frequency spike activity comprises sensing gastrointestinal electrical activity between the frequency of approximately 100 - 1000 Hz for only a presei period of time after the step of sensing low frequency slow waves.
13. The method of electrically stimulating an organ of claim 9 wherein the step of delivering slow wave electrical stimulation comprises a series of pulse trams emitted at a frequency of 30 Hz and a duration of approximately 4 seconds, each pulse lasting 330 microseconds with an amplitude of between approximately 0.5 to 10 Nolls or a current of between approximately 0.1 milliamps to 30 milliamps.
14. The method of electrically stimulating an organ of claim 9 wherein the step of delivering burst electrical stimulation comprises delivering a scries of pulse trains emitted at a frequency of 30 Hz and a duration of approximately 4 seconds, each pulse lasting 330 microseconds with an amplitude of between approximately 0.5 to 10 Nolts or a current of between approximately 0.1 milliamps to 30 milliamps.
15. A method of electrically stim ulating an organ comprising the steps of: determining the fullness of an organ within the GI tract; sensing the absence of muscular contractions in the organ; and delivering an electrical muscular contraction stimulation to the organ to thereby cause a contraction to occur in the organ.
16. The method of electrically stimulating an organ of claim 15 wherein the step of sensing the absence of muscular contractions in the organ comprises: sensing low frequency slow waves; and sensing gastrointestinal electrical activity between the frequency of approximately 100 - 1000 Hz for only a preset period of time after the step of sensing low frequency slow waves,
17. An apparatus for providing electrical stimulation to the gastrointestinal tract comprising: a pulse generator, the pulse generator generating electrical stimulation pulse trains at a pre set frequency, means for sensing low frequency slow waves; and means for sensing high frequency spike activity for a first pre set period of time after the sensing of low frequency slow waves, the means for sensing high frequency spike activity coupled to the pulse generator and inhibiting the generation of the electrical stimulation pulse trains for a second pre set period of time when the sensed high frequency spike activity exceeds a programmed high frequency spike activity value. 98/48890
23
18. The apparatus of claim 17 wherein the means for sensing low frequency slow waves comprises means for sensing gastrointestinal electrical activity between the frequency of approximately 0.017 - 0.25 Hz..
1 . The apparatus of claim 1 wherein the means for sensing high frequency spike activity for a first pre set period of time after the sensing of low frequency slow waves comprises means for sensing gastrointestinal electrical activity between the frequency of approximately 100 - 1000 Hz.
PCT/US1998/006831 1997-04-30 1998-04-06 Method and apparatus for electrical stimulation of the gastrointestinal tract WO1998048890A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67967/98A AU6796798A (en) 1997-04-30 1998-04-06 Method and apparatus for electrical stimulation of the gastrointestinal tract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/846,786 US5836994A (en) 1997-04-30 1997-04-30 Method and apparatus for electrical stimulation of the gastrointestinal tract
US08/846,786 1997-04-30

Publications (1)

Publication Number Publication Date
WO1998048890A1 true WO1998048890A1 (en) 1998-11-05

Family

ID=25298945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006831 WO1998048890A1 (en) 1997-04-30 1998-04-06 Method and apparatus for electrical stimulation of the gastrointestinal tract

Country Status (3)

Country Link
US (2) US5836994A (en)
AU (1) AU6796798A (en)
WO (1) WO1998048890A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003532A3 (en) * 1997-05-02 1999-04-08 Medtronic Inc Apparatus for treatment of gastric arrhythmias
EP0923960A1 (en) * 1997-12-15 1999-06-23 Medtronic Inc. Apparatus for electrical stimulation of the gastrointestinal tract

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8825152B2 (en) 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
JP4175662B2 (en) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ.ヴイ. Electric muscle control device
US7167748B2 (en) 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
US8321013B2 (en) 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6449507B1 (en) 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US6532388B1 (en) 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US7225019B2 (en) * 1996-04-30 2007-05-29 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6628987B1 (en) 2000-09-26 2003-09-30 Medtronic, Inc. Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US6735471B2 (en) * 1996-04-30 2004-05-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US7908003B1 (en) 1996-08-19 2011-03-15 Mr3 Medical Llc System and method for treating ischemia by improving cardiac efficiency
US8447399B2 (en) 1996-08-19 2013-05-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US7840264B1 (en) 1996-08-19 2010-11-23 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
AU4107297A (en) 1996-09-05 1998-03-26 Governors Of The University Of Alberta, The Gastro-intestinal electrical pacemaker
US5836994A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
US5861014A (en) * 1997-04-30 1999-01-19 Medtronic, Inc. Method and apparatus for sensing a stimulating gastrointestinal tract on-demand
US6477423B1 (en) * 1997-05-28 2002-11-05 Transneuronix, Inc. Medical device for use in laparoscopic surgery
EP1779890B8 (en) 1997-07-16 2009-07-08 Metacure Limited Smooth muscle controller
WO2000053257A1 (en) * 1999-03-05 2000-09-14 Impulse Dynamics Nv Blood glucose level control
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US6479523B1 (en) * 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
US6104955A (en) * 1997-12-15 2000-08-15 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract
AU2492699A (en) 1998-02-02 1999-08-16 Trustees Of Columbia University In The City Of New York, The Electrical system for weight loss and laparoscopic implantation thereof
US7468060B2 (en) * 1998-02-19 2008-12-23 Respiratory Diagnostic, Inc. Systems and methods for treating obesity and other gastrointestinal conditions
JP2000000219A (en) * 1998-06-15 2000-01-07 Gram Kk Stomach electric meter and analysis of data obtained by the same
EP1119314B1 (en) * 1998-10-06 2006-06-07 Bio Control Medical, Ltd. Control of urge incontinence
IL127481A (en) * 1998-10-06 2004-05-12 Bio Control Medical Ltd Incontinence treatment device
JP2000131356A (en) * 1998-10-27 2000-05-12 Gram Kk Spectrum analysis and indication method of time series data originating from living body
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8346363B2 (en) * 1999-03-05 2013-01-01 Metacure Limited Blood glucose level control
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8019421B2 (en) 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
US8700161B2 (en) 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
US6895278B1 (en) * 1999-04-14 2005-05-17 Transneuronix, Inc. Gastric stimulator apparatus and method for use
US6542776B1 (en) 1999-04-14 2003-04-01 Transneuronix Inc. Gastric stimulator apparatus and method for installing
US6684104B2 (en) * 1999-04-14 2004-01-27 Transneuronix, Inc. Gastric stimulator apparatus and method for installing
US6606523B1 (en) 1999-04-14 2003-08-12 Transneuronix Inc. Gastric stimulator apparatus and method for installing
IL145910A0 (en) * 1999-04-14 2002-07-25 Transneuronix Inc Gastric stimulator apparatus and method for installing
US6351665B1 (en) 1999-05-07 2002-02-26 Kenneth L Koch Method and apparatus for evaluating myoelectric signals and identifying artifact
WO2000069376A1 (en) * 1999-05-18 2000-11-23 Silhouette Medical Inc. Surgical weight control device
WO2000072912A1 (en) * 1999-05-26 2000-12-07 Impulse Dynamics Nv Local cardiac motion control using applied electrical signals and mechanical force
US7840278B1 (en) 1999-06-25 2010-11-23 Puskas John D Devices and methods for vagus nerve stimulation
US6587719B1 (en) 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
IT1313608B1 (en) 1999-08-06 2002-09-09 Valerio Cigaina EQUIPMENT FOR STIMULATION OF A COMPLETE STATE OF CONTINENCE OF THE NEOSFINTER IN THE PACK OF CONTINENT NEOSTOMIES AND
US6510332B1 (en) 1999-08-30 2003-01-21 Transneuronix, Inc. Electrode leads for use in laparoscopic surgery
US6853862B1 (en) 1999-12-03 2005-02-08 Medtronic, Inc. Gastroelectric stimulation for influencing pancreatic secretions
US20070203531A9 (en) * 1999-12-03 2007-08-30 Medtronic, Inc. Heart rate variability control of gastric electrical stimulator
US6600953B2 (en) 2000-12-11 2003-07-29 Impulse Dynamics N.V. Acute and chronic electrical signal therapy for obesity
US7096070B1 (en) 2000-02-09 2006-08-22 Transneuronix, Inc. Medical implant device for electrostimulation using discrete micro-electrodes
US6612983B1 (en) 2000-03-28 2003-09-02 Medtronic, Inc. Pancreatic secretion response to stimulation test protocol
US8467874B2 (en) * 2000-04-11 2013-06-18 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US8761903B2 (en) * 2000-10-11 2014-06-24 The Board Of Regents Of The University Of Texas Gastrointestinal electrical stimulation
US6826428B1 (en) 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
WO2001076690A1 (en) * 2000-04-11 2001-10-18 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US6592596B1 (en) 2000-05-10 2003-07-15 Scimed Life Systems, Inc. Devices and related methods for securing a tissue fold
WO2002020086A1 (en) 2000-09-07 2002-03-14 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Method and apparatus for control of bowel function
US6895279B2 (en) 2000-09-15 2005-05-17 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Method and apparatus to treat disorders of gastrointestinal peristalsis
US20020077675A1 (en) * 2000-09-26 2002-06-20 Transneuronix, Inc. Minimally invasive surgery placement of stimulation leads in mediastinal structures
US6487446B1 (en) 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US20020072780A1 (en) * 2000-09-26 2002-06-13 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US20060206160A1 (en) * 2000-11-15 2006-09-14 Transneuronix, Inc. Process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease
US6615084B1 (en) 2000-11-15 2003-09-02 Transneuronix, Inc. Process for electrostimulation treatment of morbid obesity
US7308302B1 (en) * 2000-11-20 2007-12-11 Schuler Eleanor L Device and method to record, store and broadcast specific brain waveforms to modulate body organ functioning
US20050251061A1 (en) * 2000-11-20 2005-11-10 Schuler Eleanor L Method and system to record, store and transmit waveform signals to regulate body organ function
CN1357395A (en) * 2000-12-08 2002-07-10 杭州泰士生物科技有限公司 Waveform for treating functional gastrointestinal disease and cure instrument to output the waveform
US6609025B2 (en) 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
EP1357971B1 (en) * 2001-01-05 2015-05-20 Metacure Limited Regulation of eating habits
US20030215564A1 (en) * 2001-01-18 2003-11-20 Heller Phillip F. Method and apparatus for coating an endoprosthesis
US6952613B2 (en) * 2001-01-31 2005-10-04 Medtronic, Inc. Implantable gastrointestinal lead with active fixation
US7330753B2 (en) * 2001-04-18 2008-02-12 Metacure N.V. Analysis of eating habits
US6892098B2 (en) 2001-04-26 2005-05-10 Biocontrol Medical Ltd. Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US6907295B2 (en) 2001-08-31 2005-06-14 Biocontrol Medical Ltd. Electrode assembly for nerve control
US6684105B2 (en) 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US9668690B1 (en) 2001-05-01 2017-06-06 Intrapace, Inc. Submucosal gastric implant device and method
US7979127B2 (en) 2001-05-01 2011-07-12 Intrapace, Inc. Digestive organ retention device
US7643887B2 (en) 2001-05-01 2010-01-05 Intrapace, Inc. Abdominally implanted stimulator and method
US7689284B2 (en) 2001-05-01 2010-03-30 Intrapace, Inc. Pseudounipolar lead for stimulating a digestive organ
US7020531B1 (en) 2001-05-01 2006-03-28 Intrapace, Inc. Gastric device and suction assisted method for implanting a device on a stomach wall
US20050143784A1 (en) 2001-05-01 2005-06-30 Imran Mir A. Gastrointestinal anchor with optimal surface area
US7756582B2 (en) * 2001-05-01 2010-07-13 Intrapace, Inc. Gastric stimulation anchor and method
US7747322B2 (en) 2001-05-01 2010-06-29 Intrapace, Inc. Digestive organ retention device
US6535764B2 (en) * 2001-05-01 2003-03-18 Intrapace, Inc. Gastric treatment and diagnosis device and method
US20080065169A1 (en) * 2001-05-01 2008-03-13 Intrapace, Inc. Endoscopic Instrument for Engaging a Device
US7702394B2 (en) 2001-05-01 2010-04-20 Intrapace, Inc. Responsive gastric stimulator
US7616996B2 (en) 2005-09-01 2009-11-10 Intrapace, Inc. Randomized stimulation of a gastrointestinal organ
US6678561B2 (en) * 2001-05-23 2004-01-13 Surgical Development Ag Heartburn and reflux disease treatment apparatus
KR100418034B1 (en) * 2001-05-31 2004-02-11 엘지전자 주식회사 Mask Assembly for CRT
US6622047B2 (en) * 2001-07-28 2003-09-16 Cyberonics, Inc. Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
US7885709B2 (en) 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
US8571653B2 (en) 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7778703B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Selective nerve fiber stimulation for treating heart conditions
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US7734355B2 (en) 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US7974693B2 (en) 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
US20030120328A1 (en) * 2001-12-21 2003-06-26 Transneuronix, Inc. Medical implant device for electrostimulation using discrete micro-electrodes
US20030144708A1 (en) * 2002-01-29 2003-07-31 Starkebaum Warren L. Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US7689277B2 (en) 2002-03-22 2010-03-30 Leptos Biomedical, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7551964B2 (en) 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US7702386B2 (en) 2002-03-22 2010-04-20 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US7239912B2 (en) 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7937145B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation employing frequency modulation
US20090259279A1 (en) * 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7236822B2 (en) 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US7463934B2 (en) * 2002-04-12 2008-12-09 Medtronic, Inc. Implantable medical device with captivation fixation
US20040015201A1 (en) * 2002-04-22 2004-01-22 Transneuronix, Inc. Process for electrostimulation treatment of obesity
US20040193229A1 (en) * 2002-05-17 2004-09-30 Medtronic, Inc. Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
US20030220678A1 (en) * 2002-05-21 2003-11-27 Tronnes Carole A. Adjustable implantable captivation fixation anchor-stop
US7561922B2 (en) 2004-12-22 2009-07-14 Biocontrol Medical Ltd. Construction of electrode assembly for nerve control
WO2004110550A2 (en) 2003-06-13 2004-12-23 Biocontrol Medical Ltd. Vagal stimulation for anti-embolic therapy
US8204591B2 (en) 2002-05-23 2012-06-19 Bio Control Medical (B.C.M.) Ltd. Techniques for prevention of atrial fibrillation
US7321793B2 (en) 2003-06-13 2008-01-22 Biocontrol Medical Ltd. Vagal stimulation for atrial fibrillation therapy
US7844346B2 (en) 2002-05-23 2010-11-30 Biocontrol Medical Ltd. Electrode assembly for nerve control
US20040088022A1 (en) * 2002-07-26 2004-05-06 Transneuronix, Inc. Process for electrostimulation treatment of morbid obesity
US6990376B2 (en) * 2002-12-06 2006-01-24 The Regents Of The University Of California Methods and systems for selective control of bladder function
US7627384B2 (en) * 2004-11-15 2009-12-01 Bio Control Medical (B.C.M.) Ltd. Techniques for nerve stimulation
US8880192B2 (en) 2012-04-02 2014-11-04 Bio Control Medical (B.C.M.) Ltd. Electrode cuffs
DE10300069A1 (en) * 2003-01-03 2004-07-22 Grönemeyer, Dietrich H. W., Prof. Dr.med. EP trainer
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7613515B2 (en) 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
EP1606011B1 (en) 2003-03-10 2015-08-19 Impulse Dynamics N.V. Apparatus for delivering electrical signals to modify gene expression in cardiac tissue
DE10316177B4 (en) * 2003-04-10 2007-05-31 Cardiac Pacemakers, Inc., St. Paul Pacemaker electrode arrangement
US20040215283A1 (en) * 2003-04-23 2004-10-28 Antoine Camps Electrical stimulation of the colon to treat chronic constipation
US7742818B2 (en) * 2003-05-19 2010-06-22 Medtronic, Inc. Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof
US7620454B2 (en) * 2003-05-19 2009-11-17 Medtronic, Inc. Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof
US8060197B2 (en) 2003-05-23 2011-11-15 Bio Control Medical (B.C.M.) Ltd. Parasympathetic stimulation for termination of non-sinus atrial tachycardia
JP4943841B2 (en) 2003-06-20 2012-05-30 メタキュアー リミティド Gastrointestinal methods and devices for use in treating disorders
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US7194301B2 (en) 2003-10-06 2007-03-20 Transneuronic, Inc. Method for screening and treating patients at risk of medical disorders
US7499759B2 (en) * 2003-10-24 2009-03-03 Cardiac Pacemakers, Inc. Distal or proximal fixation of over-the-tether myocardial leads
WO2005039691A1 (en) * 2003-10-24 2005-05-06 Cardiac Pacemakers, Inc. Myocardial lead attachment system
US20050096514A1 (en) * 2003-11-01 2005-05-05 Medtronic, Inc. Gastric activity notification
WO2005051486A1 (en) * 2003-11-28 2005-06-09 University Technologies International Inc. Method and apparatus for gastrointestinal motility control
US8396560B2 (en) * 2004-11-18 2013-03-12 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US7177693B2 (en) * 2004-01-07 2007-02-13 Medtronic, Inc. Gastric stimulation for altered perception to treat obesity
US7052167B2 (en) * 2004-02-25 2006-05-30 Vanderschuit Carl R Therapeutic devices and methods for applying therapy
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
WO2006119467A2 (en) 2005-05-04 2006-11-09 Impulse Dynamics Nv Protein activity modification
US7551599B2 (en) * 2004-03-29 2009-06-23 Corrigent Systems Ltd. Layer-3 network routing with RPR layer-2 visibility
US20050222637A1 (en) * 2004-03-30 2005-10-06 Transneuronix, Inc. Tachygastrial electrical stimulation
US20050222638A1 (en) * 2004-03-30 2005-10-06 Steve Foley Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders
JP5175092B2 (en) 2004-06-01 2013-04-03 クワラタ トレーディング リミティド In vitro technology using stem cells
US7803195B2 (en) 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US7664551B2 (en) * 2004-07-07 2010-02-16 Medtronic Transneuronix, Inc. Treatment of the autonomic nervous system
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
US8612016B2 (en) 2004-08-18 2013-12-17 Metacure Limited Monitoring, analysis, and regulation of eating habits
US7519433B2 (en) * 2004-08-25 2009-04-14 Medtronic Transneuronix, Inc. Gastrointestinal stimulation lead
US7623924B2 (en) 2004-08-31 2009-11-24 Leptos Biomedical, Inc. Devices and methods for gynecologic hormone modulation in mammals
US8214047B2 (en) 2004-09-27 2012-07-03 Advanced Neuromodulation Systems, Inc. Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions
EP1827571B1 (en) 2004-12-09 2016-09-07 Impulse Dynamics NV Protein activity modification
US8609082B2 (en) 2005-01-25 2013-12-17 Bio Control Medical Ltd. Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8260426B2 (en) * 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US7515965B2 (en) * 2005-02-23 2009-04-07 Medtronic, Inc. Implantable medical device providing adaptive neurostimulation therapy for incontinence
US8700163B2 (en) 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US20060212086A1 (en) * 2005-03-17 2006-09-21 Mintchev Martin P Gastrointestinal volume manipulation
US8244371B2 (en) 2005-03-18 2012-08-14 Metacure Limited Pancreas lead
US8265758B2 (en) * 2005-03-24 2012-09-11 Metacure Limited Wireless leads for gastrointestinal tract applications
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
US20060247718A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Dual mode electrical stimulation to treat obesity
US20060247717A1 (en) * 2005-04-28 2006-11-02 Medtronic, Inc. Electrical stimulation of the gastrointestinal tract to regulate motility
US7310557B2 (en) * 2005-04-29 2007-12-18 Maschino Steven E Identification of electrodes for nerve stimulation in the treatment of eating disorders
US7835796B2 (en) * 2005-04-29 2010-11-16 Cyberonics, Inc. Weight loss method and device
US7899540B2 (en) * 2005-04-29 2011-03-01 Cyberonics, Inc. Noninvasively adjustable gastric band
US7974202B2 (en) 2005-05-06 2011-07-05 Corrigent Systems, Ltd. Tunnel provisioning with link aggregation
US7711419B2 (en) 2005-07-13 2010-05-04 Cyberonics, Inc. Neurostimulator with reduced size
US20070016262A1 (en) * 2005-07-13 2007-01-18 Betastim, Ltd. Gi and pancreatic device for treating obesity and diabetes
US7840280B2 (en) 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US7856273B2 (en) 2005-07-28 2010-12-21 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US8660647B2 (en) 2005-07-28 2014-02-25 Cyberonics, Inc. Stimulating cranial nerve to treat pulmonary disorder
US20070027486A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Medical devices for enhancing intrinsic neural activity
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US20070078494A1 (en) * 2005-09-23 2007-04-05 Mintchev Martin P Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US7509175B2 (en) 2006-08-03 2009-03-24 Intrapace, Inc. Method and devices for stimulation of an organ with the use of a transectionally placed guide wire
US8442841B2 (en) 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US7620455B2 (en) 2005-10-25 2009-11-17 Cyberonics, Inc. Cranial nerve stimulation to treat eating disorders
US8428731B2 (en) 2005-10-27 2013-04-23 Cyberonics, Inc. Sequenced therapy protocols for an implantable medical device
US8694118B2 (en) 2005-10-28 2014-04-08 Cyberonics, Inc. Variable output ramping for an implantable medical device
US20070100388A1 (en) * 2005-10-31 2007-05-03 Medtronic, Inc. Implantable medical device providing adaptive neurostimulation therapy for incontinence
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
US7996079B2 (en) * 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US20070173890A1 (en) * 2006-01-24 2007-07-26 Cyberonics, Inc. Stimulation mode adjustment for an implantable medical device
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US8195296B2 (en) 2006-03-03 2012-06-05 Ams Research Corporation Apparatus for treating stress and urge incontinence
US8027718B2 (en) * 2006-03-07 2011-09-27 Mayo Foundation For Medical Education And Research Regional anesthetic
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
ES2538726T3 (en) 2006-03-29 2015-06-23 Dignity Health Vagus nerve stimulation system
US7545740B2 (en) * 2006-04-07 2009-06-09 Corrigent Systems Ltd. Two-way link aggregation
US20080183237A1 (en) * 2006-04-18 2008-07-31 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US7962220B2 (en) * 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
WO2007136712A2 (en) * 2006-05-17 2007-11-29 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
WO2007137026A2 (en) 2006-05-18 2007-11-29 Cedars-Sinai Medical Center Electrical stimulation of the lower esophageal sphincter
US9020597B2 (en) 2008-11-12 2015-04-28 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US8295926B2 (en) 2006-06-02 2012-10-23 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US7738961B2 (en) * 2006-10-09 2010-06-15 Endostim, Inc. Method and apparatus for treatment of the gastrointestinal tract
US9724510B2 (en) 2006-10-09 2017-08-08 Endostim, Inc. System and methods for electrical stimulation of biological systems
US20150224310A1 (en) 2006-10-09 2015-08-13 Endostim, Inc. Device and Implantation System for Electrical Stimulation of Biological Systems
US9345879B2 (en) 2006-10-09 2016-05-24 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US11577077B2 (en) 2006-10-09 2023-02-14 Endostim, Inc. Systems and methods for electrical stimulation of biological systems
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US7697525B2 (en) * 2006-12-21 2010-04-13 Corrigent Systems Ltd. Forwarding multicast traffic over link aggregation ports
US7706875B2 (en) 2007-01-25 2010-04-27 Cyberonics, Inc. Modulation of drug effects by vagus nerve stimulation
AU2008216316A1 (en) 2007-02-13 2008-08-21 Virender K. Sharma Method and apparatus for electrical stimulation of the pancreatico-biliary system
US7904175B2 (en) * 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7962214B2 (en) * 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US8417329B2 (en) * 2007-05-09 2013-04-09 Metacure Ltd. Analysis and regulation of food intake
US8032222B2 (en) * 2007-06-19 2011-10-04 Loushin Michael K H Device for electrically and mechanically stimulating a compartment in a body
WO2009013749A2 (en) * 2007-07-24 2009-01-29 Betastim, Ltd. Duodenal eating sensor
US20090118777A1 (en) * 2007-08-09 2009-05-07 Kobi Iki Efferent and afferent splanchnic nerve stimulation
WO2009043168A1 (en) * 2007-10-05 2009-04-09 Uti Limited Partnership Feedback controlled gastro-intestinal stimulation
US7949397B1 (en) * 2007-10-29 2011-05-24 Pacesetter, Inc. Implantable medical device capable of depressing appetite to control obesity using stochastic resonance electrical stimulation
US20090204173A1 (en) 2007-11-05 2009-08-13 Zi-Ping Fang Multi-Frequency Neural Treatments and Associated Systems and Methods
US8510902B2 (en) 2007-12-03 2013-08-20 Dri-Eaz Products, Inc. Air induction hard surface cleaning tool with an internal baffle
US7765006B2 (en) * 2007-12-13 2010-07-27 Leto Medical, Llc Method and apparatus for providing continence to a gastrointestinal ostomy
US9579506B2 (en) 2008-01-25 2017-02-28 Flint Hills Scientific, L.L.C. Contingent cardio-protection for epilepsy patients
WO2009094609A1 (en) 2008-01-25 2009-07-30 Sharma Virender K Device and implantation system for electrical stimulation of biological systems
US8565885B2 (en) * 2008-01-30 2013-10-22 The Board Of Regents Of The University Of Texas System Ileal electrical stimulation
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US8423130B2 (en) 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
US20100087706A1 (en) * 2008-09-30 2010-04-08 Intrapace, Inc. Lead Access
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US9079028B2 (en) 2008-10-09 2015-07-14 Virender K. Sharma Method and apparatus for stimulating the vascular system
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US9327121B2 (en) 2011-09-08 2016-05-03 Nevro Corporation Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US20100191304A1 (en) 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
WO2010093951A1 (en) * 2009-02-13 2010-08-19 Intrapace, Inc. Endoscopic forceps with removable handle
US8538532B2 (en) * 2009-03-03 2013-09-17 Medtronic, Inc. Electrical stimulation therapy to promote gastric distention for obesity management
US9539433B1 (en) 2009-03-18 2017-01-10 Astora Women's Health, Llc Electrode implantation in a pelvic floor muscular structure
US20110087076A1 (en) 2009-04-03 2011-04-14 Intrapace, Inc. Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
ES2624748T3 (en) 2009-04-22 2017-07-17 Nevro Corporation Selective high frequency modulation of the spinal cord for pain inhibition with reduced side effects, and associated systems and methods
EP2756864B1 (en) 2009-04-22 2023-03-15 Nevro Corporation Spinal cord modulation systems for inducing paresthetic and anesthetic effects
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US8498710B2 (en) 2009-07-28 2013-07-30 Nevro Corporation Linked area parameter adjustment for spinal cord stimulation and associated systems and methods
BR112012001910A2 (en) 2009-09-21 2019-09-24 Medtronic Inc waveforms for electrical stimulation therapy
US8380312B2 (en) 2009-12-31 2013-02-19 Ams Research Corporation Multi-zone stimulation implant system and method
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US11717681B2 (en) 2010-03-05 2023-08-08 Endostim, Inc. Systems and methods for treating gastroesophageal reflux disease
US8447403B2 (en) 2010-03-05 2013-05-21 Endostim, Inc. Device and implantation system for electrical stimulation of biological systems
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8788045B2 (en) 2010-06-08 2014-07-22 Bluewind Medical Ltd. Tibial nerve stimulation
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
WO2012045030A2 (en) 2010-10-01 2012-04-05 Intrapace, Inc. Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors
US9186504B2 (en) 2010-11-15 2015-11-17 Rainbow Medical Ltd Sleep apnea treatment
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
AU2011336606B2 (en) 2010-11-30 2016-06-23 Nevro Corporation Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
CN103596515A (en) 2011-04-14 2014-02-19 恩多斯提姆公司 Systems and methods for treating gastroesophageal reflux disease
US9999767B2 (en) 2011-06-27 2018-06-19 E-Motion Medical, Ltd. Esophageal stimulation system
US9037245B2 (en) 2011-09-02 2015-05-19 Endostim, Inc. Endoscopic lead implantation method
US9925367B2 (en) 2011-09-02 2018-03-27 Endostim, Inc. Laparoscopic lead implantation method
US9731112B2 (en) 2011-09-08 2017-08-15 Paul J. Gindele Implantable electrode assembly
US20150018728A1 (en) 2012-01-26 2015-01-15 Bluewind Medical Ltd. Wireless neurostimulators
US8676331B2 (en) 2012-04-02 2014-03-18 Nevro Corporation Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
WO2013184841A1 (en) 2012-06-05 2013-12-12 Texas Heart Institute Location determining endotracheal tube and methods
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US9833614B1 (en) 2012-06-22 2017-12-05 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
EP2888000A4 (en) 2012-08-23 2016-07-06 Endostim Inc Device and implantation system for electrical stimulation of biological systems
WO2014087337A1 (en) 2012-12-06 2014-06-12 Bluewind Medical Ltd. Delivery of implantable neurostimulators
EP2934667A1 (en) 2012-12-24 2015-10-28 E-Motion Medical, Ltd. Gi tract stimulation devices and methods
US9498619B2 (en) 2013-02-26 2016-11-22 Endostim, Inc. Implantable electrical stimulation leads
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US9895539B1 (en) 2013-06-10 2018-02-20 Nevro Corp. Methods and systems for disease treatment using electrical stimulation
CN105848708A (en) 2013-09-03 2016-08-10 恩多斯蒂姆股份有限公司 Methods and systems of electrode polarity switching in electrical stimulation therapy
US10149978B1 (en) 2013-11-07 2018-12-11 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control
EP3200724A4 (en) 2014-09-29 2018-03-28 The Regents of The University of California Flexible and stretchable electrodes for gastrointestinal implants
US9597507B2 (en) 2014-10-31 2017-03-21 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential
US9682234B2 (en) 2014-11-17 2017-06-20 Endostim, Inc. Implantable electro-medical device programmable for improved operational life
US9764127B2 (en) 2014-12-19 2017-09-19 Cardiac Pacemakers, Inc. Medical lead anchoring
CN104548349A (en) * 2014-12-31 2015-04-29 清华大学 Electric pulse stimulation testing device and testing system with electric pulse stimulation testing device
CN104548342A (en) * 2014-12-31 2015-04-29 清华大学 Implantable electric pulse stimulation system
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
WO2016138176A1 (en) 2015-02-24 2016-09-01 Elira Therapeutics Llc Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US10188866B2 (en) 2015-06-24 2019-01-29 Impulse Dynamics Nv Simple control of complex bio-implants
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
AU2017211121B2 (en) 2016-01-25 2022-02-24 Nevro Corp. Treatment of congestive heart failure with electrical stimulation, and associated systems and methods
US10799701B2 (en) 2016-03-30 2020-10-13 Nevro Corp. Systems and methods for identifying and treating patients with high-frequency electrical signals
US11446504B1 (en) 2016-05-27 2022-09-20 Nevro Corp. High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods
WO2018094207A1 (en) 2016-11-17 2018-05-24 Endostim, Inc. Modular stimulation system for the treatment of gastrointestinal disorders
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US20180353764A1 (en) 2017-06-13 2018-12-13 Bluewind Medical Ltd. Antenna configuration
US11672979B2 (en) 2017-12-05 2023-06-13 David Buck Device to induce electrical muscle relaxation for airway management
AU2020207940A1 (en) 2019-01-17 2021-08-12 Nevro Corp. Sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection, and associated systems and methods
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
CN111407307A (en) * 2020-04-17 2020-07-14 华中科技大学同济医学院附属协和医院 Electric stimulation massage device and electric stimulation massage method for enterokinesia
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator
CN115137980B (en) * 2022-06-23 2023-08-18 迈达佩思医疗科技(天津)有限责任公司 Percutaneous nerve electrical stimulation device synchronized with gastrointestinal electricity and method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3411507A (en) * 1964-04-01 1968-11-19 Medtronic Inc Method of gastrointestinal stimulation with electrical pulses
EP0571938A2 (en) * 1992-05-29 1993-12-01 Valerio Cigaina Process and device for treating obesity and motor disorders of the stomach
WO1994001172A1 (en) * 1992-07-10 1994-01-20 Douglas Donald D A percutaneously placed electrical intestinal pacemaker
EP0759308A2 (en) * 1995-08-17 1997-02-26 Medtronic, Inc. Cardiac assist device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2237648A1 (en) * 1973-07-16 1975-02-14 Zacouto Fred Suppositories for introduction into digestive tract - contg. vibrators or medicaments
US4153059A (en) * 1977-10-25 1979-05-08 Minnesota Mining And Manufacturing Company Urinary incontinence stimulator system
FR2453630B1 (en) * 1979-04-13 1983-10-21 Agronomique Inst Nat Rech COLON ELECTROMYOGRAPHY ENDOLUMINAL PROBE
SU1651918A1 (en) * 1988-04-04 1991-05-30 Днепропетровский медицинский институт Method for treating the cases of chronic constipation
US4981470A (en) * 1989-06-21 1991-01-01 Synectics Medical, Inc. Intraesophageal catheter with pH sensor
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
IT1272447B (en) * 1993-05-25 1997-06-23 Cicaina Valerio PROCEDURE AND DEVICE FOR THE DIETETIC OPTIMIZATION OF GROWING PIGS
US5540730A (en) * 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5836994A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Method and apparatus for electrical stimulation of the gastrointestinal tract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3411507A (en) * 1964-04-01 1968-11-19 Medtronic Inc Method of gastrointestinal stimulation with electrical pulses
EP0571938A2 (en) * 1992-05-29 1993-12-01 Valerio Cigaina Process and device for treating obesity and motor disorders of the stomach
WO1994001172A1 (en) * 1992-07-10 1994-01-20 Douglas Donald D A percutaneously placed electrical intestinal pacemaker
EP0759308A2 (en) * 1995-08-17 1997-02-26 Medtronic, Inc. Cardiac assist device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARNET T.G. ET AL: "Microcomputer analysis and display of canine small intestinal electrical activity", MEDICAL AND BIOLOGICAL ENGINEERING AND COMPUTING, vol. 25, no. 6, November 1987 (1987-11-01), STEVENHAGE, pages 672 - 676, XP002067561 *
CRENNER F. ET AL: "Analogue automated analysis of small intestinal electromyogram", MEDICAL AND BIOLOGICAL ENGINEERING AND COMPUTING, vol. 20, no. 2, March 1982 (1982-03-01), STEVENHAGE, pages 151-158, XP002067224 *
POUSSE A ET AL: "DETECTION OF INTESTINAL SPIKE BURSTS USING A MICROCOMPUTER", PROCEEDINGS OF THE ANNUAL CONFERENCE OF THE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, BOSTON, NOV. 13 - 16, 1987, vol. VOL. 3, no. CONF. 9, 13 November 1987 (1987-11-13), INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 1224/1225, XP000040142 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003532A3 (en) * 1997-05-02 1999-04-08 Medtronic Inc Apparatus for treatment of gastric arrhythmias
EP0923960A1 (en) * 1997-12-15 1999-06-23 Medtronic Inc. Apparatus for electrical stimulation of the gastrointestinal tract

Also Published As

Publication number Publication date
US5995872A (en) 1999-11-30
US5836994A (en) 1998-11-17
AU6796798A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
US5836994A (en) Method and apparatus for electrical stimulation of the gastrointestinal tract
US6104955A (en) Method and apparatus for electrical stimulation of the gastrointestinal tract
US6091992A (en) Method and apparatus for electrical stimulation of the gastrointestinal tract
US6216039B1 (en) Method and apparatus for treating irregular gastric rhythms
US5861014A (en) Method and apparatus for sensing a stimulating gastrointestinal tract on-demand
US9370654B2 (en) High frequency stimulation to block laryngeal stimulation during vagal nerve stimulation
US5690691A (en) Gastro-intestinal pacemaker having phased multi-point stimulation
US8731663B2 (en) Vagal stimulation during atrial tachyarrhythmia to facilitate cardiac resynchronization therapy
US6128535A (en) Automatic capture verification in multisite cardiac pacing
US5540730A (en) Treatment of motility disorders by nerve stimulation
US20050070974A1 (en) Obesity and eating disorder stimulation treatment with neural block
US20080132968A1 (en) Cardiac activity control of gastric electrical stimulator
CN113543843A (en) Method and apparatus for stimulation
US20040193229A1 (en) Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
US20060247717A1 (en) Electrical stimulation of the gastrointestinal tract to regulate motility
US20200147376A1 (en) Multiple type sleep apnea
US7274960B2 (en) Method and apparatus for treating aneurysms by electrostimulation
US7949397B1 (en) Implantable medical device capable of depressing appetite to control obesity using stochastic resonance electrical stimulation
US20130289636A1 (en) Timed implantable therapy delivery device
EP3787737A2 (en) Left ventricular capture and synchronization verification using a single multi-electrode coronary sinus lead
EP4223360A1 (en) Integrated sleep apnea and at least one of cardiac monitoring and cardiac therapy
CN116531660A (en) Integrated sleep apnea and at least one of cardiac monitoring and cardiac therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998547004

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA